vs
爱齐科技（ALGN）与通用电气医疗（GEHC）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是爱齐科技的5.4倍（$5.7B vs $1.0B）。爱齐科技净利率更高（13.0% vs 10.3%，领先2.6%）。通用电气医疗同比增速更快（7.1% vs 5.3%）。过去两年通用电气医疗的营收复合增速更高（10.7% vs 2.5%）
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、核磁共振、女性健康筛查、X射线系统）、超声、患者护理解决方案（聚焦远程患者监测、麻醉呼吸护理、心脏病诊断、婴幼儿照护）及制药诊断业务。
ALGN vs GEHC — 直观对比
营收规模更大
GEHC
是对方的5.4倍
$1.0B
营收增速更快
GEHC
高出1.8%
5.3%
净利率更高
ALGN
高出2.6%
10.3%
两年增速更快
GEHC
近两年复合增速
2.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $5.7B |
| 净利润 | $135.8M | $588.0M |
| 毛利率 | 65.3% | 39.7% |
| 营业利润率 | 14.8% | 14.5% |
| 净利率 | 13.0% | 10.3% |
| 营收同比 | 5.3% | 7.1% |
| 净利润同比 | 30.8% | -18.4% |
| 每股收益（稀释后） | $1.88 | $1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGNGEHC
| Q4 25 | $1.0B | $5.7B | ||
| Q3 25 | $995.7M | $5.1B | ||
| Q2 25 | $1.0B | $5.0B | ||
| Q1 25 | $979.3M | $4.8B | ||
| Q4 24 | $995.2M | $5.3B | ||
| Q3 24 | $977.9M | $4.9B | ||
| Q2 24 | $1.0B | $4.8B | ||
| Q1 24 | $997.4M | $4.7B |
净利润ALGNGEHC
| Q4 25 | $135.8M | $588.0M | ||
| Q3 25 | $56.8M | $446.0M | ||
| Q2 25 | $124.6M | $486.0M | ||
| Q1 25 | $93.2M | $564.0M | ||
| Q4 24 | $103.8M | $721.0M | ||
| Q3 24 | $116.0M | $470.0M | ||
| Q2 24 | $96.6M | $428.0M | ||
| Q1 24 | $105.0M | $374.0M |
毛利率ALGNGEHC
| Q4 25 | 65.3% | 39.7% | ||
| Q3 25 | 64.2% | 38.7% | ||
| Q2 25 | 69.9% | 39.6% | ||
| Q1 25 | 69.5% | 42.1% | ||
| Q4 24 | 70.0% | 42.8% | ||
| Q3 24 | 69.7% | 41.7% | ||
| Q2 24 | 70.3% | 41.4% | ||
| Q1 24 | 70.0% | 40.9% |
营业利润率ALGNGEHC
| Q4 25 | 14.8% | 14.5% | ||
| Q3 25 | 9.7% | 12.7% | ||
| Q2 25 | 16.1% | 13.1% | ||
| Q1 25 | 13.4% | 13.2% | ||
| Q4 24 | 14.5% | 15.1% | ||
| Q3 24 | 16.6% | 13.9% | ||
| Q2 24 | 14.3% | 12.6% | ||
| Q1 24 | 15.5% | 11.6% |
净利率ALGNGEHC
| Q4 25 | 13.0% | 10.3% | ||
| Q3 25 | 5.7% | 8.7% | ||
| Q2 25 | 12.3% | 9.7% | ||
| Q1 25 | 9.5% | 11.8% | ||
| Q4 24 | 10.4% | 13.6% | ||
| Q3 24 | 11.9% | 9.7% | ||
| Q2 24 | 9.4% | 8.8% | ||
| Q1 24 | 10.5% | 8.0% |
每股收益（稀释后）ALGNGEHC
| Q4 25 | $1.88 | $1.28 | ||
| Q3 25 | $0.78 | $0.98 | ||
| Q2 25 | $1.72 | $1.06 | ||
| Q1 25 | $1.27 | $1.23 | ||
| Q4 24 | $1.40 | $1.58 | ||
| Q3 24 | $1.55 | $1.02 | ||
| Q2 24 | $1.28 | $0.93 | ||
| Q1 24 | $1.39 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $4.5B |
| 总债务越低越好 | — | $10.0B |
| 股东权益账面价值 | $4.0B | $10.4B |
| 总资产 | $6.2B | $36.9B |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ALGNGEHC
| Q4 25 | $1.1B | $4.5B | ||
| Q3 25 | $1.0B | $4.0B | ||
| Q2 25 | $901.2M | $3.7B | ||
| Q1 25 | $873.0M | $2.5B | ||
| Q4 24 | $1.0B | $2.9B | ||
| Q3 24 | $1.0B | $3.5B | ||
| Q2 24 | $761.4M | $2.0B | ||
| Q1 24 | $865.8M | $2.6B |
总债务ALGNGEHC
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $10.3B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $9.2B | ||
| Q1 24 | — | $9.3B |
股东权益ALGNGEHC
| Q4 25 | $4.0B | $10.4B | ||
| Q3 25 | $4.0B | $10.0B | ||
| Q2 25 | $3.9B | $9.7B | ||
| Q1 25 | $3.8B | $9.2B | ||
| Q4 24 | $3.9B | $8.4B | ||
| Q3 24 | $3.9B | $8.3B | ||
| Q2 24 | $3.8B | $7.8B | ||
| Q1 24 | $3.8B | $7.4B |
总资产ALGNGEHC
| Q4 25 | $6.2B | $36.9B | ||
| Q3 25 | $6.2B | $36.1B | ||
| Q2 25 | $6.2B | $35.5B | ||
| Q1 25 | $6.1B | $33.6B | ||
| Q4 24 | $6.2B | $33.1B | ||
| Q3 24 | $6.4B | $33.9B | ||
| Q2 24 | $6.2B | $31.9B | ||
| Q1 24 | $6.2B | $32.2B |
负债/权益比ALGNGEHC
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 1.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.2M | — |
| 自由现金流经营现金流 - 资本支出 | $187.3M | — |
| 自由现金流率自由现金流/营收 | 17.9% | — |
| 资本支出强度资本支出/营收 | 3.4% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.64× | — |
| 过去12个月自由现金流最近4个季度 | $490.8M | — |
8季度趋势，按日历期对齐
经营现金流ALGNGEHC
| Q4 25 | $223.2M | — | ||
| Q3 25 | $188.7M | — | ||
| Q2 25 | $128.7M | $94.0M | ||
| Q1 25 | $52.7M | $250.0M | ||
| Q4 24 | $286.1M | — | ||
| Q3 24 | $263.7M | — | ||
| Q2 24 | $159.8M | $-119.0M | ||
| Q1 24 | $28.7M | $419.0M |
自由现金流ALGNGEHC
| Q4 25 | $187.3M | — | ||
| Q3 25 | $169.0M | — | ||
| Q2 25 | $107.2M | $8.0M | ||
| Q1 25 | $27.4M | $98.0M | ||
| Q4 24 | $263.1M | — | ||
| Q3 24 | $233.9M | — | ||
| Q2 24 | $106.4M | $-183.0M | ||
| Q1 24 | $19.3M | $274.0M |
自由现金流率ALGNGEHC
| Q4 25 | 17.9% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 10.6% | 0.2% | ||
| Q1 25 | 2.8% | 2.1% | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 10.3% | -3.8% | ||
| Q1 24 | 1.9% | 5.9% |
资本支出强度ALGNGEHC
| Q4 25 | 3.4% | 2.4% | ||
| Q3 25 | 2.0% | 2.1% | ||
| Q2 25 | 2.1% | 1.7% | ||
| Q1 25 | 2.6% | 3.2% | ||
| Q4 24 | 2.3% | 1.9% | ||
| Q3 24 | 3.0% | 1.9% | ||
| Q2 24 | 5.2% | 1.3% | ||
| Q1 24 | 0.9% | 3.1% |
现金转化率ALGNGEHC
| Q4 25 | 1.64× | — | ||
| Q3 25 | 3.33× | — | ||
| Q2 25 | 1.03× | 0.19× | ||
| Q1 25 | 0.57× | 0.44× | ||
| Q4 24 | 2.76× | — | ||
| Q3 24 | 2.27× | — | ||
| Q2 24 | 1.66× | -0.28× | ||
| Q1 24 | 0.27× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGN
暂无分部数据
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
